Global Synthetic Bone Graft Substitutes Market Size Likely to Grow at a CAGR of 6.9% By 2035

The market size of the global synthetic bone graft substitutes will be estimated at USD 1.4 billion in 2025 and is expected to grow between USD 1.5 billion in 2026 and about USD 2.7 billion by 2035 with a current CAGR of 6.9% during the period of 2026 to 2035.

Synthetic Bone Graft Substitutes Market Revenue and Trends

Synthetic bone graft substitutes are specifically designed and manufactured biomaterials that can take the place of, support, and even aid the healing of the bone during the surgery. They even make the healing process of bone regeneration go by naturally, but the one underneath the patient's bone will be different from the others and will be done by using different methods compared to autografts or allografts. The production of these substitutes includes the use of various materials such as ceramics (which involve calcium phosphate, hydroxyapatite, and beta-tricalcium phosphate), polymers, or composite formulations that mimic the structural and biological properties of natural bone.

The main application of synthetic bone graft substitutes is as osteoconductive scaffolds, and they provide the new bone that can grow on the top of the foreign material that, if it is not biological, is either integrated into or resorbed by the body in a gradual manner. The frequent application of these substitutes in orthopedic, spinal, dental, trauma, and craniomaxillofacial surgeries is mainly due to their advantages of consistent quality product, unlimited supply, reduced disease transmission risks, and no morbidity at donor sites, and all these make the biological bone grafts a very safe and reliable alternative.

What are the Factors That Have a Significant Contribution to the Growth of the Synthetic Bone Graft Substitutes Market?

The synthetic bone graft substitutes market is being pushed forward by the combination of many factors such as an increase in orthopedic, spinal and trauma surgeries, an ageing population with a greater occurrence of osteoporosis and degenerative disorders, continuous research and development of safe and off-the-shelf alternatives to autografts/allografts, such as bioactive ceramics, composites, growth factor integration, and 3D printed, patient-specific scaffolds, expanding healthcare infrastructure and surgical capacity in emerging markets, active R&D and a healthy product pipeline; pricing, local manufacturing and reimbursement dynamics as economic forces that determine access and adoption. North America, by region, is still the largest and most advanced market with high surgical volumes, favorable reimbursement, strong R&D and the presence of leading med-tech companies driving rapid uptake of high-end, premium products.

Europe is showing gradual growth, mainly due to an older population, strong clinical standards and stringent regulations that support high-quality, evidence-based substitutes, although price pressures and differing national reimbursement policies inhibit uptake. Asia-Pacific is expected to be the fastest growing market due to the increase in hospital infrastructure, greater healthcare and patient pool spending (mainly in China and India), domestic manufacturing, and acceptance of synthetic options. These are some of the factors contributing to the rapid growth in this region. However, price sensitivity is shaping the product mix towards mid- and low-cost solutions.

Segment Insight

By End User

The hospitals segment is growing at a significant rate over the projected period. The increase can be attributed to the fact that there is an increasing volume of complex surgical procedures performed in hospitals. Hospital settings are the main places where large orthopedic, spinal fusion, trauma, and craniomaxillofacial surgeries are done, and all these surgeries often need the support of bone grafting for the process of bone repair and regeneration.

The continual occurrence of road accidents, sports injuries, older people suffering from bone disorders, and degenerative spinal conditions has led to more patients being admitted for surgery, thus indirectly increasing the demand for synthetic bone graft substitutes.

Regional Insights

The synthetic bone graft substitutes market has been dominated by North America. The presence of major players in the region, particularly US drives the market growth.

The key players in the area continuously spent a lot of capital on the synthetic bone graft substitutes and launched innovative solutions in the market. For instance, in August 2024, the new bone allograft, which was made by regenerative health company LifeNet Health in partnership with Johnson & Johnson MedTech, was unveiled by the company as its initial step towards the demineralized bone matrix (DBM) market.

Besides, the Asia Pacific market has the highest rate of growth in the synthetic bone graft substitutes market. The growing investment in healthcare infrastructure and increasing number of accidents annually are major factors driving the market expansion in the area.

Report Scope

Recent Developments

• In January 2025, NovaBone Products, the leading company in bioactive synthetic bone graft solutions, made news by signing a strategic distribution deal with BEGO, a well-known and reputable provider of innovative implantology solutions. This partnership is the introduction of NovaBone’s advanced Dental Putty with Cartridge Dispenser into the European market, which is considered a major milestone in the process of providing the most modern dental graft solutions to the dental practitioners of the area. (Source: https://novabone.com/about/press-releases/novabone-partners-with-bego-for-european-launch-of-dental-putty)

List of the prominent players in the Synthetic Bone Graft Substitutes Market:

• Medtronic plc

• DePuy Synthes (Johnson & Johnson)

• Zimmer Biomet Holdings Inc.

• Stryker Corporation

• Baxter International Inc.

• Arthrex Inc.

• Smith & Nephew plc

• NuVasive Inc.

• RTI Surgical Holdings Inc.

• Integra LifeSciences Holdings Corporation

• BioHorizons Implant Systems Inc.

• Geistlich Pharma AG

• BioMimetic Therapeutics (or similar emerging biologics)

• AlloSource

• Cortex (Zimmer/BioHorizons partner or subsidiary)

• Others

The Synthetic Bone Graft Substitutes Market is segmented as follows:

By Product Type

• Ceramic-based

• Polymer-based

• Composites-based

By Application

• Spinal Fusion

• Craniomaxillofacial

• Hip Surgery

• Dental Bone Grafting

• Others

By End User

• Hospitals

• Ambulatory Surgical Centres (ASCs)

• Orthopedic Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America